Interviewed by Dr. Vivian Liu, CEO of IMPELINNO GmbH
[ Introduction on Mr. Ning Zhang ]
Mr. Zhang is the Executive Secretary of the China Medical Innovation Alliance and the General Manager of Beijing KANGWEI MEDICAL INNOVATION Co., Ltd. With a background in health industry promotion at the China Technology Exchange, he has been instrumental in guiding significant research initiatives, including the 13th Five-Year Plan for technology market construction. He pioneered the “Consensus and Guidelines for Medical Innovation Transformation” in China and introduced the first “China Hospital Innovation Transformation Ranking”. Mr. Zhang has also led various national medical innovation competitions and training programs, assisting top-tier hospitals in innovation transformation, commercialization and overseeing specialty platforms in particular in cardiovascular, neuro-intervention areas and kidney diseases. His expertise lies in policy research, project operations, and medical technology transformation.
[ Interview Summary ]
In the dynamic world of medical device innovation, understanding the nuances of the market is paramount. Our in-depth interview series with Mr. Ning Zhang, a prominent figure in China’s MedTech sector, offers invaluable insights for foreign MedTech SMEs, innovators, and clinicians looking to navigate and succeed in this vast landscape.
[ Session Highlights ]
Session 1
The Role of Clinical Experts: Our journey begins with a deep dive into the world of clinical experts, the KOLs. Mr. Zhang emphasizes their indispensable contributions, from the initial idea to real-world application. China’s unique approach in this domain sets its clinicians apart, offering a fresh perspective on global MedTech innovation.
Session 2
Specialty Medical Innovation Translation Alliances: In our second session, the focus shifts to these groundbreaking alliances. In contrast to gathering the stakeholders in medical technology from various disease areas, these Specialty Medical Innovation Translation Alliances are specialized in targeted diseases, including cardiovascular diseases, kidney diseases and neurosciences. Mr. Zhang elucidates how they’re shaping the future of MedTech, fostering collaborations, and ensuring that innovations are not only pioneering but also impactful and relevant.
Session 3
China’s Distinctive MedTech Approach: Delving deeper, our third session explores what truly sets China apart. Drawing parallels with Switzerland’s innovation ecosystem, Mr. Zhang introduces an alliance operation methodology that focuses on specific diseases first and then looks for commonalities in medical device innovation across different diseases. He introduces the concept of pan-vascularization, proposed by some of China’s top clinical experts and the importance of engaging with innovators. A significant highlight is his guidance on navigating the challenges of financing in China’s dynamic MedTech environment.
Session 4
Strategies for Success in China’s MedTech Sector: As China faces the challenges of an aging population, the demand for top-tier medical care is on the rise. Mr. Zhang shares his opinion on the medtech innovation trend in China and provides a roadmap for both SMEs and multinationals, emphasizing the importance of innovation and the potential of forging local partnerships.
Session 5
Europe-China MedTech Collaboration: Our series culminates in a comprehensive discussion on the strategies vital for European MedTech stakeholders to thrive in China. Mr. Zhang underscores the significance of strategic partnerships, early clinical collaboration, and the art of selecting the right partner.
For MedTech SMEs, innovators, and clinicians aiming to make their mark in China, these insights from Mr. Zhang are indispensable. As China continues to be a major player in shaping the future of medical innovation, understanding its landscape, challenges, and opportunities is crucial.
Join us in this enlightening series on our YouTube channel as we bridge the MedTech worlds of Europe and China, offering a roadmap to success in one of the world’s most dynamic and promising markets.
